Publications

Bipolar Disorders

April 2012

Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine
Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, Spyker DA, Kehne JH, Cassella JV

Journal of Clinical Pharmacology

February 2012

The Pharmacokinetics and Pharmacodynamics of Zaleplon Delivered as a Thermally Generated Aerosol in a Single Breath to Volunteers
Michael J. Avram, Daniel A. Spyker, John H. Kehne and James V. Cassella

Journal of Aerosol Medicine and Pulmonary Drug Delivery

February 2011

Assessing the Temperature of Thermally Generated Inhalation Aerosols
Peter D. Noymer, Dan J. Myers, James V. Cassella, Ryan Timmons

Journal of Clinical Psychiatry

January 2011

Efficacy and Safety of Loxapine for Inhalation in the Treatment of Agitation in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Michael H. Allen, MD et al

The British Journal of Psychiatry

January 2011

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
Michael D. Lesem, MD et al

Journal of Pharmaceutical and Biomedical Analysis

July 29, 2010

Forced Degradation of Fentanyl: Identification and Analysis of Impurities and Degradants
Garg et al

Journal of Aerosol Medicine and Pulmonary Drug Delivery

August 2010, Vol. 23, No. 4: 253-260

In Vitro Aerosol Deposition in the Oropharyngeal Region for Staccato Loxapine
Dinh et al

Respiratory Drug Delivery 2010

Vol 1 (2010): pp 11-20

The Staccato System: Inhaler Design Characteristics for Rapid Treatment of CNS Disorders
Noymer et al

Clinical Therapeutics

Vol. 32, No. 3 March 2010

Systematic Reviews of Assessment Measures and Pharmacologic Treatments for Agitation
S.L. Zeller et al

APA 2010 – The Cardiovascular Safety of Inhaled Loxapine (534kb PDF)

May 2010

The cardiovascular safety of inhaled loxapine.
Daniel A. Spyker, MD, PhD, Mildred D. Gottwald, PharmD, Robert S. Fishman, MD, James V. Cassella, PhD

APA 2010 – Treating Agitation with Inhaled Loxapine (576kb PDF)

May 2010

Efficacy Analyses in Patients with Schizophrenia or Bipolar Disorder
Robert S. Fishman, MD, Daniel A. Spyker, MD, PhD, James V. Cassella, PhD

The Journal of Clinical Pharmacology

2010; 50: 169-179

Pharmacokinetics of Loxapine Following Inhalation of a Thermally Generated Aerosol in Healthy Volunteers
Daniel A. Spyker, PhD, MD, Patrik Munzar, MD and James V. Cassella, PhD

Future Neurology

September 2009, Vol. 4, No. 5, Pages 539-545 , DOI 10.2217/fnl.09.42

Drug Evaluation Inhaled loxapine for acute agitation in schizophrenia and bipolar disorder
Kimberly Nordstrom‌†

APA 2009 (576kb PDF)

Inhaled Loxapine Rapidly Improves Acute Agitation in Patients with Bipolar Disorder
Robert Fishman, James Cassella, Daniel Spyker, AZ-004 Study Group

APA 2009 (524kb PDF)

Inhaled Loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients
James Cassella, Robert Fishman, Daniel Spyker, AZ-004 Study Group